ReviewRheumatology (Oxford, England)2025
Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 1: plasma exchange should not be used indiscriminately.
Review in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience.Rheumatology (Oxford, England) · 2026Observational
- Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
ANCA-associated vasculitis (AAV) is a heterogeneous autoimmune disease marked by varying organ involvement and outcomes. Plasma exchange, a method of removing native plasma and replacing it with crystalloid, albumin or donor plasma, can deplete autoantibodies and may help control autoimmune diseases rapidly. In AAV, several randomized controlled trials have been performed but, individually, had mixed results. The best data available, through meta-analysis, suggest the effects of plasma exchange in AAV are limited to improving kidney outcomes with a low likelihood of other benefits but also an increase in the risk of serious infections. As such, the use of plasma exchange in AAV should be limited to patients at risk of a poor kidney outcome as all others are more likely to experience harm than benefit. By estimating the risk of kidney failure and serious infections with and without plasma exchange, healthcare providers can help patients with AAV make informed choices about the use of plasma exchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.